Deutsche Bank AG Has $4.53 Million Stake in Sanofi (NASDAQ:SNY)

Deutsche Bank AG decreased its stake in shares of Sanofi (NASDAQ:SNY) by 74.9% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 93,994 shares of the company’s stock after selling 280,338 shares during the period. Deutsche Bank AG’s holdings in Sanofi were worth $4,531,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Mondrian Investment Partners LTD grew its holdings in Sanofi by 9.4% in the 3rd quarter. Mondrian Investment Partners LTD now owns 1,435,319 shares of the company’s stock valued at $69,197,000 after buying an additional 123,140 shares during the last quarter. Brookfield Asset Management Inc. acquired a new stake in Sanofi in the 2nd quarter valued at approximately $4,031,000. Bellevue Group AG acquired a new stake in Sanofi in the 2nd quarter valued at approximately $3,581,000. Dodge & Cox grew its holdings in Sanofi by 1.8% in the 2nd quarter. Dodge & Cox now owns 70,280,548 shares of the company’s stock valued at $3,700,974,000 after buying an additional 1,219,164 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Sanofi by 7.2% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 44,539 shares of the company’s stock valued at $2,345,000 after buying an additional 2,983 shares during the last quarter. 9.37% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have issued reports on SNY. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating and set a $44.00 target price on the stock. in a report on Wednesday. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Sanofi in a report on Thursday, October 14th. SVB Leerink raised Sanofi from a “market perform” rating to an “outperform” rating in a report on Monday, September 27th. Finally, HSBC raised Sanofi from a “hold” rating to a “buy” rating in a report on Monday, November 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $44.00.

Shares of NASDAQ:SNY opened at $51.93 on Friday. Sanofi has a 1-year low of $45.17 and a 1-year high of $54.26. The firm has a market capitalization of $130.95 billion, a PE ratio of 17.72, a PEG ratio of 1.16 and a beta of 0.61. The business’s 50 day moving average is $49.71 and its 200-day moving average is $50.25. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.28.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, October 28th. The company reported $1.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.18 by $0.11. The business had revenue of $12.30 billion during the quarter, compared to the consensus estimate of $12.49 billion. Sanofi had a return on equity of 25.76% and a net margin of 16.60%. On average, sell-side analysts predict that Sanofi will post 3.68 EPS for the current year.

About Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.

Read More: Options Trading – Understanding Strike Price

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.